HALOZYME THERAPEUTICS, INC. 8-K

What Happened Halozyme Therapeutics, Inc. (HALO) filed a Form 8-K reporting that on April 22, 2026 its Board of Directors amended the company’s Bylaws. The amendments revise Section 2.5 to permit directors to be removed at any time, with or without cause, by holders of a majority of the shares then entitled to vote in a director election. The amendments also revise Section 1.12 to clarify that any action required or permitted at an annual or special stockholder meeting may not be taken without a meeting, consistent with Article FIFTH of the company’s Certificate of Incorporation.

Key Details

• Effective date of bylaw amendments: April 22, 2026; 8-K filed April 24, 2026.
• Section 2.5 change: directors may be removed at any time, with or without cause, by holders of a majority of shares entitled to vote for directors.
• Section 1.12 change: clarifies that actions required or permitted at annual/special stockholder meetings may not be taken without holding a meeting (consistent with Certificate of Incorporation).
• The full text of the amended Bylaws is furnished as Exhibit 3.1 to the filing.

Why It Matters These bylaw changes affect corporate governance and the balance of power between the board and stockholders. Allowing removal of directors by a simple majority vote can make it easier for holders of a controlling or majority voting position to change board composition. The clarification that certain stockholder actions cannot be taken without a meeting reinforces that formal meetings (not written consents) are required for those actions under the company’s governing documents. Investors should note the change when assessing governance, shareholder rights, and potential implications for future board contests or corporate actions.